93019-52-4

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 5177-43-5 2,3,4,5-tetrahydro-1H-benzodiazepine dihydrochloride 

Downstream Products

• 1442654-18-3 C₁₇H₂₀N₂O₂S 
• 1442654-17-2 5-(4-methylphenylsulfonyl)-5,6,7,10,11,12-hexahydro-4H-cyclopenta[c][1,4]diazepino[6,7,1-ij]quinolin-8-ium triflate 
• 1442654-20-7 5-(4-methylphenylsulfonyl)-5,6,7,10,11,12-hexahydro-4H-cyclopenta[c][1,4]diazepino[6,7,1-ij]quinolin-8-ium iodide 
• 1442654-19-4 (9aR,12aS)-5-(4-methylphenylsulfonyl)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline 

Relevant academic research and scientific papers

Asymmetric synthesis of vabicaserin via oxidative multicomponent annulation and asymmetric hydrogenation of a 3,4-substituted quinolinium salt

An efficient, asymmetric synthesis of the 5-HT2C agonist vabicaserin in four chemical steps and 54% overall yield from commercially available benzodiazepine was achieved. The synthesis was highlighted by a novel oxidative, multicomponent reaction to affect the quinolinium ring assembly in one step followed by an unprecedented asymmetric hydrogenation of a 3,4-substituted quinolinium salt.